Effect of Increlex® on Children With Crohn Disease

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Crohn Disease
Interventions
DRUG

rhIGF (Increlex)

rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tercica

INDUSTRY

lead

Nationwide Children's Hospital

OTHER